ClinicalTrials.gg
RecruitingNCT07141251BAO-G-02Updated Oct 15, 2026

Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)

An interventional study of BAO-G in Thoracoabdominal Aortic Aneurysm, Endovascular Repair and Complex Aortic Aneurysms, sponsored by Peking Union Medical College Hospital. Recruiting at 11 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Jan 2022, registered Aug 2025).
  • Started Jan 2022; still recruiting 4 years 10 months later.
Updated Oct 15, 2026Eligibility revisedDesign changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Multi-Branch AOrtic Reconstruction With G-iliac System (BAO-G) Technique is a novel technique of endovascular repair of complex aortic aneurysm, which using off-the-shelf iliac branched devices to reconstruct the visceral branches. This study aims to verify the perioperative safety and 5-year efficacy of BAO-G technique in the endovascular treatment of complex aortic aneurysms through a prospective, multicenter, open-label, single-arm clinical trial, and to provide evidence for the selection of clinical procedures for complex aortic aneurysm patients in the future.

02

Conditions studied

  • Thoracoabdominal Aortic Aneurysm
  • Endovascular Repair
  • Complex Aortic Aneurysms

Keywords

  • BAO-G technique
  • iliac-branched devices
  • endovascular repair
  • complex aortic aneurysm
03

In context

Aortic Aneurysm, Thoracoabdominal

63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.

This study's planned enrollment of 60 is below the median of 80 across 41 interventional studies indexed under Aortic Aneurysm, Thoracoabdominal.

Browse Aortic Aneurysm, Thoracoabdominal studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with Crawford type Ⅰ- Ⅴ thoracoabdominal aortic aneurysm or complex abdominal aortic aneurysm, with a healthy proximal landing zone (>20mm length, angulation \<60°) in the descending aorta and maximum aneurysm diameter ≥4cm
  2. Patients with pseudoaneurysms, post-dissection aneurysmal degeneration, or failure of previous EVAR were also eligible if the pathology involved the visceral aortic segment;
  3. Scheduled for endovascular aortic repair with commercially available iliac branch devices for visceral artery reconstruction
  4. Signed and committed to protocol-defined follow-up

Exclusion criteria

Exclusion Criteria:

  1. Acquired language barrier, intellectual decline, cognitive impairment, or mental illness preventing
  2. Uncontrolled diseases (e.g., Takayasu arteritis, systemic lupus erythematosus, vasculitis)
  3. End-stage renal/hepatic/cardiac/pulmonary failure or diagnosed within 5 years, likely to cause mortality during follow-up
  4. Active bleeding or coagulopathy within 6 months (high bleeding risk)
  5. Uncontrolled hypertension (resting SBP >180 mmHg or DBP >110 mmHg)
  6. Uncontrolled diabetes (fasting blood glucose >16.7 mmol/L)
  7. Severe hepatic/renal dysfunction (serum creatinine >3 mg/dL, /AST >3×)
  8. Concurrent participation in other interventional clinical trials
  9. Pregnancy or perinatal status
  10. Refusal to sign informed consent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    BAO-G group

    Procedure: BAO-G

Interventions

  • ProcedureBAO-G

    Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.

06

What researchers measure

Primary outcomes

  1. Incidence of primary technical success

    The preoperative planned protocol was successfully completed, including aneurysm repair and visceral branch reconstruction, with no aneurysm-related conversion to open surgery/death, no type I/III endoleak, and no branch occlusion within 30 days postoperatively.

    Time frame: within 30 days postoperatively

  2. Incidence of clinical success

    The preoperative planned protocol was successfully completed, including aneurysm repair and visceral branch reconstruction, without significant disabling permanent clinical sequelae, and with the patient remained free from aneurysm-related mortality or secondary interventions due to aneurysm progression during follow-up.

    Time frame: within 5 years postoperatively

Secondary outcomes

  1. Incidence of aneurysm-related death occurred during perioperative period

    All deaths occurring before discharge or within 30 days postoperatively that were attributable to the surgical treatment (including stent-induced retrograde dissection, procedure-related aneurysm rupture, branch occlusion causing severe visceral ischemia, etc.) or aneurysm progression, unless there is clear evidence demonstrating the patient's death was unrelated to the aneurysm.

    Time frame: within 30 days postoperatively

  2. Incidence of rupture of aneurysms

    Time frame: within 5 years postoperatively

  3. Incidence of permanent paraplegia

    Time frame: within 5 years postoperatively

  4. Incidence of permanent lower limb monoparesis

    Time frame: within 5 years postoperatively

  5. Incidence of new-onset dialysis-dependent renal failure

    Time frame: within 5 years postoperatively

  6. Incidence of severe bowel ischemia

    Time frame: within 5 years postoperatively

  7. Incidence of disabling stroke

    Time frame: within 5 years postoperatively

  8. Intraoperative blood loss

    Time frame: during the operation

  9. Incidence of vascular access complications

    Time frame: within 5 years postoperatively

  10. Operative time

    Time frame: during the operation

  11. Length of stay (LOS)

    Time frame: From the date of hospital admission until the date of hospital discharge, assessed up to 5 years

  12. Length of stay for planned staged procedures

    Time frame: From the date of hospital admission until the date of hospital discharge, assessed up to 5 years

  13. Incidence of adjunctive primary technical success

    Required unplanned additional endovascular techniques (e.g., parallel stent-graft technique) to achieve aneurysm exclusion, without type I/III endoleak and with branch patency for 30 days

    Time frame: within 30 days postoperatively

  14. Incidence of secondary technical success

    Required unplanned surgical conversion to complete aneurysm exclusion, without type I/III endoleak and with branch patency for 30 days.

    Time frame: within 30 days postoperatively

  15. Incidence of stent migration

    Definitive stent migration (≥10mm axial displacement) confirmed by evaluation using anatomical landmarks on the first postoperative CT.

    Time frame: within 5 years postoperatively

  16. Incidence of aneurysm enlargement

    Aneurysm enlargement (\>5mm maximum diameter increase) demonstrated on perioperative and follow-up CTA.

    Time frame: within 5 years postoperatively

  17. Incidence of significant distal embolization

    Stent-induced lower limb arterial embolism with ischemia requiring surgical intervention, amputation, or resulting in death.

    Time frame: within 5 years postoperatively

  18. Incidence of Stent- or procedure-related exploratory laparotomy

    Adverse event requiring exploratory laparotomy due to stent- or procedure-related complications

    Time frame: within 5 years postoperatively

  19. Incidence of aortoiliac stent occlusion

    Occlusion of aortic branch stents, iliac branch devices, or iliac limb extensions

    Time frame: within 5 years postoperatively

  20. Rate of primary stent patency

    Patency of branch stents and bridging stents, with no in-stent restenosis or occlusion.

    Time frame: within 5 years postoperatively

  21. Rate of adjunctive primary stent patency

    Secondary intervention was required due to branch/bridging stent kinking or in-stent restenosis, with patency restored after the additional procedure.

    Time frame: within 5 years postoperatively

  22. Rate of secondary stent patency

    Patency restored after secondary intervention for branch/bridging stent occlusion.

    Time frame: within 5 years postoperatively

  23. Incidence of reoperation

    Unplanned reoperation related to stent or procedure within the intended treatment zone, excluding access-related reinterventions and procedures outside the target anatomical area.

    Time frame: within 5 years postoperatively

  24. Incidence of acute kidney injury

    A perioperative increase in serum creatinine to 1.5-2 times the preoperative baseline value according to RIFLE criteria.

    Time frame: within 30 days postoperatively

  25. Incidence of Type I endoleak

    Endoleak originating from proximal or distal seal zones

    Time frame: within 5 years postoperatively

  26. Incidence of Type Ia endoleak

    Endoleak originating from the proximal seal zone of aortic stent

    Time frame: within 5 years postoperatively

  27. Incidence of Type Ib endoleak

    Endoleak originating from the distal seal zone of aortic or iliac stents

    Time frame: within 5 years postoperatively

  28. Incidence of Type Ic endoleak

    Endoleak originating from the distal seal zone of visceral artery stents

    Time frame: within 5 years postoperatively

  29. Incidence of Type II endoleak

    Endoleak originating from aortic branches (e.g., inferior mesenteric artery, lumbar arteries, intercostal arteries)

    Time frame: within 5 years postoperatively

  30. Incidence of Type III endoleak

    Endoleak originating from stent junctions or device structural failure

    Time frame: within 5 years postoperatively

  31. Incidence of Type IIIa endoleak

    Endoleak due to aortoiliac stent junctional failure

    Time frame: within 5 years postoperatively

  32. Incidence of Type IIIb endoleak

    Endoleak caused by fracture or disruption of visceral artery stents within branch vessels

    Time frame: within 5 years postoperatively

  33. Incidence of Type IIIc endoleak

    Endoleak into the aortic aneurysm sac due to poor connection or structural failure between visceral branch bridging stents and aortic branch stents

    Time frame: within 5 years postoperatively

  34. Incidence of Type IV endoleak

    Endoleak due to stent-graft fabric permeability

    Time frame: within 5 years postoperatively

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Dec 2030, 107 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 26, 2025
StartActual
Jan 1, 2022
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion removed
What changed in the criteria
Inclusion criteria
  • EditedDiagnosed with Crawford type IIIⅠ-IV Ⅴ thoracoabdominal aortic aneurysm or complex abdominal aortic aneurysm, with a healthy proximal landing zone (>20mm length, angulation <60°) in the descending aorta and maximum aneurysm diameter ≥4cm
  • AddedPatients with pseudoaneurysms, post-dissection aneurysmal degeneration, or failure of previous EVAR were also eligible if the pathology involved the visceral aortic segment;
Exclusion criteria
  • RemovedPrior aortic surgery with stent-graft or prosthetic vascular graft implantation
Oct 15, 2026
Design
Phase 1→Not applicable
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosed with Crawford type IIIⅠ-IV Ⅴ thoracoabdominal aortic aneurysm or complex abdominal aortic aneurysm, with a healthy proximal landing zone (>20mm length, angulation <60°) in the descending aorta and maximum aneurysm diameter ≥4cm
    • AddedPatients with pseudoaneurysms, post-dissection aneurysmal degeneration, or failure of previous EVAR were also eligible if the pathology involved the visceral aortic segment;
    Exclusion criteria
    • RemovedPrior aortic surgery with stent-graft or prosthetic vascular graft implantation
    Design Phase 1→Not applicable
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07141251
Collaborators
Fudan University, First Affiliated Hospital, Sun Yat-Sen University, Changhai Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing Anzhen Hospital, RenJi Hospital, Hainan General Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Chongqing Medical University, Affiliated Hospital of Jining Medical University
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Jan 1, 2022
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Oct 15, 2026

Study contacts

Bao Liu
Contact
liubao7286@163.com
+86010-69152592

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion